文献类型：期刊文献

英文题名：Integration of metabolomics and network pharmacology technology to explain the effect mechanisms of Danggui Buxue decoction in vascular dementia

作者：Fan, Qin[1,2,3];Liu, Xinhong[4];Zhang, Yanying[1];Kang, Wanrong[1];Si, Shanshan[1];Zhang, Hongmei[1]

第一作者：Fan, Qin;樊秦

通信作者：Fan, Q[1]

机构：[1]Gansu Univ Chinese Med, 35 Dingxidong Rd, Lanzhou 730000, Peoples R China;[2]Coll Gansu Prov, Key Lab Chem & Qual Tradit Chinese Med, Lanzhou, Peoples R China;[3]Gansu Prov Engn Lab TCM Standardizat Technol & Pop, Lanzhou, Peoples R China;[4]Gansu Agr Univ, Coll Vet Med, Lanzhou, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, 35 Dingxidong Rd, Lanzhou 730000, Peoples R China.|[10735]甘肃中医药大学;

年份：2024

卷号：38

期号：4

外文期刊名：BIOMEDICAL CHROMATOGRAPHY

收录：;EI(收录号：20240315408138);Scopus(收录号：2-s2.0-85182441635);WOS:【SCI-EXPANDED(收录号:WOS:001144207300001)】；

基金：This work was supported by the Higher Education Innovation Fund Project of Gansu Province (2022A-073), the Innovation Base and Talent Plan Project of Science and Technology Department of Gansu Province (21JR7RA565), and Lanzhou Science and Technology Bureau Project (2022-RC-44).

语种：英文

外文关键词：Danggui Buxue decoction; metabolomics; molecular docking; network pharmacology; vascular dementia

摘要：Danggui Buxue decoction (DBD) is a traditional Chinese medicine herbal decoction that has a good therapeutic effect on vascular dementia (VaD). However, its pharmacodynamic substances and underlying mechanisms are ambiguous. The work aimed to decipher the pharmacodynamic substances and molecular mechanisms of DBD against VaD rats based on gas chromatography-mass spectrometry metabonomics, network pharmacology, molecular docking, and experimental verification. The results indicated that DBD significantly improved the learning abilities and cognitive impairment in the VaD rat model. Integration analysis of the metabolomics and network pharmacology approach revealed that DBD might primarily affect arachidonic acid (AA) and inositol phosphate metabolic pathways by regulating the platelet activation signaling pathways. Six core targets (TNF [tumor necrosis factor], IL-6 [interleukin 6], PTGS2 [prostaglandin-endoperoxide synthase 2], MAPK1, MAPK3, and TP53) in the platelet activation signaling pathways also had a good affinity to seven main active components (saponins, organic acids, flavonoids, and phthalides) of DBD through the verification of molecular docking. Enzyme-linked immunosorbent assay results (ELISA) showed that the levels of TNF, IL-6, PTGS2, thromboxane B2, and caspase-3 in the platelet activation signaling pathway can be regulated by DBD. Our results indicated that DBD treated VaD mainly by modulating the platelet activation signaling pathway, and AA and inositol phosphate metabolism.